Cobenfy vs Clozapine: What the Evidence Shows So Far in Schizophrenia

Creator: Ryan S. Sultan, MD
Published: 2026-11-12

By Ryan S. Sultan, MD
Psychiatrist · Columbia University Irving Medical Center
Published November 12, 2026 · 6-minute read

A search of PubMed and ClinicalTrials.gov in November 2026 found no randomized trial comparing Cobenfy (xanomeline and trospium chloride) with clozapine, and no randomized trial of Cobenfy in treatment-resistant schizophrenia. The FDA approved Cobenfy on September 26, 2024, for schizophrenia in adults, based on two 5-week inpatient trials.^{1, 2, 3, 4} Both trials excluded people with a history of treatment resistance.^{5, 6}

Clozapine is indicated for severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.⁷ In a meta-analysis, 40.1% of people with treatment-resistant schizophrenia responded to it.⁸

What Cobenfy is

Cobenfy is a capsule that combines xanomeline and trospium chloride. The FDA described it as the first antipsychotic approved for schizophrenia that targets cholinergic receptors as opposed to dopamine receptors.¹ Its labeled indication is the treatment of schizophrenia in adults, and the current label carries no boxed warning.²

What EMERGENT-2 and EMERGENT-3 found

EMERGENT-2 randomized 252 people with schizophrenia, 126 to Cobenfy and 126 to placebo, in a 5-week inpatient trial in the United States. The mean change in the Positive and Negative Syndrome Scale (PANSS) total score was -21.2 points with Cobenfy and -11.6 points with placebo, a difference of -9.6 points (95% CI -13.9 to -5.2).³

EMERGENT-3 randomized 256 people, 125 to Cobenfy and 131 to placebo, at 30 inpatient sites in the US and Ukraine. The change in PANSS total score was -20.6 points with Cobenfy and -12.2 points with placebo, a difference of -8.4 points (95% CI -12.4 to -4.3).⁴

The most common adverse events in EMERGENT-3 were nausea, dyspepsia, vomiting, and constipation. Nausea was reported by 19.2% of participants on Cobenfy and 1.6% on placebo, and vomiting by 16.0% and 0.8%.⁴ In EMERGENT-2, weight gain was reported as an adverse event by no participants on Cobenfy and one on placebo.³

Both registry records define that exclusion as failure to respond to 2 adequate courses of medication or having required clozapine within the last 12 months.^{5, 6}

The one-year data are open-label, and most participants left early

Two 52-week studies followed people on Cobenfy without a comparison group. In EMERGENT-4, 156 of the 366 people who completed the phase 3 trials enrolled, and 34 of them (21.8%) completed the year.⁹ In EMERGENT-5, 566 participants received at least one dose, and 277 (48.9%) completed the trial.¹⁰ The label counts 150 patients with at least 1 year of exposure.²

Cobenfy for treatment-resistant schizophrenia

The published data found in treatment-resistant illness are uncontrolled. One is a retrospective analysis from five Texas state hospitals covering 20 inpatients with treatment-resistant schizophrenia, all but one also prescribed a dopamine receptor blocking medication. Fourteen of the 20 (70%) discontinued Cobenfy during the study period, 9 for intolerability and 12 for lack of effectiveness, with some patients counted in both groups. The average global improvement score was 4, which means no change. The authors called for larger controlled trials.¹¹

Cobenfy and clozapine together

No randomized trial of the combination was found as of November 2026. In the Texas series, 6 of the 20 patients were also prescribed clozapine.¹¹ A 2026 report of two patients with clozapine-resistant schizophrenia described limited response when Cobenfy was added.¹²

ARISE was a randomized, placebo-controlled trial of Cobenfy as an add-on, a 6-week outpatient study in people with an inadequate response to their current antipsychotic. Clozapine was not among the permitted background medications, and treatment-resistant schizophrenia was an exclusion. In results posted on ClinicalTrials.gov, ARISE missed its primary endpoint: the change in PANSS total score was -14.3 points with Cobenfy (190 analyzed) and -12.2 points with placebo (196 analyzed), a difference of -2.0 points (95% CI -4.51 to 0.47; p = 0.1115).¹³ No peer-reviewed report of the trial was found in PubMed as of November 2026.

How the two medications compare

Cobenfy and clozapine: labeling and evidence
Feature	Cobenfy	Clozapine
Indication	Schizophrenia in adults	Severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment; reducing the risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder
Evidence in treatment-resistant illness	No randomized trial found as of November 2026. Phase 3 trials excluded these patients. One retrospective series of 20	40.1% responded in a meta-analysis
Monitoring	Liver enzymes and bilirubin before starting and as clinically indicated. Heart rate at baseline and as clinically indicated	Absolute neutrophil count at baseline and regularly throughout treatment
Contraindications	Urinary retention, moderate or severe hepatic impairment, gastric retention, untreated narrow-angle glaucoma, history of hypersensitivity to Cobenfy or trospium chloride	History of hypersensitivity to clozapine or another component
Boxed warning	None	Severe neutropenia; orthostatic hypotension, bradycardia, and syncope; seizure; myocarditis, pericarditis, and cardiomyopathy; increased mortality in elderly patients with dementia-related psychosis
Most common adverse reactions	Nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, gastroesophageal reflux disease	Sedation, dizziness or vertigo, headache, tremor, tachycardia, hypotension, syncope, hypersalivation, sweating, dry mouth, visual disturbances, constipation, nausea, fever

Source: Cobenfy prescribing information (DailyMed, current as of November 2026) and Clozaril prescribing information, revised June 2025.^{2, 7} Adverse reaction cutoffs: at least 5% and twice placebo (Cobenfy), at least 5% (clozapine). Evidence row: ClinicalTrials.gov records, the Texas series, and a clozapine response meta-analysis.^{5, 6, 11, 8}

The Cobenfy label also states that it is not recommended for patients with mild hepatic impairment or with moderate or severe renal impairment.² I've written separately about clozapine side effects and the clozapine blood test schedule.

Limitations of the evidence

This evidence has limitations. First, the efficacy trials lasted 5 weeks and enrolled inpatients. Second, the ARISE figures are registry postings that haven't been through peer review, and the treatment-resistant data come from 20 patients with no control group. Nevertheless, the trial record is consistent: Cobenfy's efficacy was shown in adults who had not been classified as treatment-resistant.

What this means for a treatment decision

For schizophrenia that hasn't responded adequately to standard antipsychotics, clozapine has a labeled indication and meta-analysis response data.^{7, 8} Cobenfy's trials enrolled a different population. Whether either medication fits a particular person, and any change to a current medication, is a decision made with the prescriber. The page on when to start clozapine covers how treatment resistance is defined.

Frequently asked questions

Is Cobenfy better than clozapine for treatment-resistant schizophrenia?

A November 2026 search of PubMed and ClinicalTrials.gov found no randomized trial comparing them and no randomized trial of Cobenfy in treatment-resistant schizophrenia. Cobenfy's phase 3 trials excluded people with a history of treatment resistance. In a meta-analysis, 40.1% of people with treatment-resistant schizophrenia responded to clozapine.^{5, 6, 8}

Can you take Cobenfy and clozapine together?

No randomized trial of the combination was found as of November 2026. The ARISE trial of Cobenfy added to another antipsychotic did not permit clozapine as the background medication and missed its primary endpoint in results posted on ClinicalTrials.gov. Any combination is a decision made with the prescriber.¹³

When was Cobenfy approved, and on what evidence?

The FDA approved Cobenfy for schizophrenia in adults on September 26, 2024. The two phase 3 trials, EMERGENT-2 with 252 participants and EMERGENT-3 with 256, lasted 5 weeks and showed PANSS differences from placebo of -9.6 and -8.4 points.^{1, 3, 4}

Does Cobenfy work for treatment-resistant schizophrenia?

No randomized trial in that group was found as of November 2026. In a retrospective series of 20 state hospital inpatients with treatment-resistant schizophrenia, all but one also prescribed a dopamine receptor blocking medication, 70% discontinued Cobenfy and the average global improvement score indicated no change.¹¹

Is there long-term data on Cobenfy?

Two 52-week open-label studies exist, with no comparison group. In EMERGENT-4, 34 of 156 enrolled participants (21.8%) completed the year, and in EMERGENT-5, 277 of 566 (48.9%) completed the trial.^{9, 10}

In a crisis: call or text 988, or go to the nearest emergency department. A first episode of psychosis belongs in a hospital-based or coordinated specialty care program.

I start and manage clozapine in an outpatient practice in Chelsea, Manhattan. Details are on the schizophrenia care in NYC page. Clozapine should not be stopped, skipped, or restarted without the prescriber. This page is general information and does not replace an evaluation.